
Canada Cardiac Rhythm Management Devices Market Outlook to 2033 - Cardiac Resynchronisation Therapy (CRT), Implantable Cardioverter Defibrillators (ICD) and Others
Description
Canada Cardiac Rhythm Management Devices Market Outlook to 2033 - Cardiac Resynchronisation Therapy (CRT), Implantable Cardioverter Defibrillators (ICD) and Others
Canada Cardiac Rhythm Management Devices Market Outlook to 2033 - Cardiac Resynchronisation Therapy (CRT), Implantable Cardioverter Defibrillators (ICD) and Others
Summary
GlobalData’s “Canada Cardiac Rhythm Management Devices Market Outlook to 2033” is a comprehensive databook report, covering key market data on the Canada Cardiac Rhythm Management Devices market. The databook report provides value (USD), volume (units) and average prices (USD) - Cardiac Resynchronisation Therapy (CRT), Implantable Cardioverter Defibrillators (ICD) and Others.
The Canada Cardiac Rhythm Management Devices Market report provides key information and data on -
- Annualized market revenues (USD), volume (units) and average prices (USD) data for each of the market segments. Data is provided from 2018 to 2033.
- 2023 company share and distribution share data for Cardiac Rhythm Management Devices Market.
- Global corporate-level profiles of key companies operating within the Canada Cardiac Rhythm Management Devices Market. Based on the availability of data for the particular category and country, information related to pipeline products, news and deals is also available in the report.
Canada Cardiac Rhythm Management Devices is segmented as follows -
- Cardiac Resynchronisation Therapy (CRT)
- Pacemakers
- Implantable Cardioverter Defibrillators (ICD)
- Implantable Loop Recorders (ILR)
Canada Cardiac Rhythm Management Devices Market report helps you to develop -
- Business strategies by identifying the key market segments poised for strong growth in the future.
- Market-entry and market expansion strategies.
- Design competition strategies by identifying who-stands-where in the market.
- Develop investment strategies by identifying the key market segments expected to register strong growth in the near future.
- Understand the key distribution channels and what’s the most preferred mode of product distribution - Identify, understand and capitalize.
Table of Contents
46 Pages
- 1 Table of Contents
- 1.1 List of Tables
- 1.2 List of Figures
- 2 Introduction
- 2.1 What Is This Report About?
- 2.2 Cardiac Rhythm Management Devices Market Segmentation
- 2.3 Definitions of Markets Covered in the Report
- 3 Cardiac Rhythm Management Devices Market, Canada
- 3.1 Cardiac Rhythm Management Devices Market, Canada, Revenue ($m), 2018-2033
- 3.1.1 Cardiac Resynchronisation Therapy (CRT) Market, Canada, Revenue ($m), by Segment, 2018-2033
- 3.1.2 Implantable Cardioverter Defibrillators (ICD) Market, Canada, Revenue ($m), by Segment, 2018-2033
- 3.1.3 Pacemakers Market, Canada, Revenue ($m), by Segment, 2018-2033
- 3.2 Cardiac Rhythm Management Devices Market, Canada, Volume (Units), 2018-2033
- 3.2.1 Cardiac Resynchronisation Therapy (CRT) Market, Canada, Volume (Units), by Segment, 2018-2033
- 3.2.2 Implantable Cardioverter Defibrillators (ICD) Market, Canada, Volume (Units), by Segment, 2018-2033
- 3.2.3 Pacemakers Market, Canada, Volume (Units), by Segment, 2018-2033
- 3.3 Cardiac Rhythm Management Devices Market, Canada, Average Price ($), 2018-2033
- 3.4 Cardiac Rhythm Management Devices Market, Canada, Distribution Share by Revenue ($m), 2023
- 3.5 Cardiac Rhythm Management Devices Market, Canada, Company Share by Revenue ($m), 2023
- 4 Overview of Key Companies in Canada, Cardiac Rhythm Management Devices Market
- 4.1 Medtronic Plc
- 4.1.1 Company Overview
- 4.2 Abbott Laboratories
- 4.2.1 Company Overview
- 4.3 Boston Scientific Corp
- 4.3.1 Company Overview
- 4.4 Biotronik SE & Co KG
- 4.4.1 Company Overview
- 4.5 MicroPort Scientific Corp
- 4.5.1 Company Overview
- 5 Cardiac Rhythm Management Devices Market Pipeline Products
- 6 Financial Deals Landscape
- 6.1 Debt Offerings
- 6.1.1 Ventripoint Diagnostics Raises USD0.69 Million in First Tranche Non-Brokered Private Placement of 10% Convertible Debenture Due 2027
- 7 Recent Developments
- 7.1 Corporate Communications
- 7.1.1 Feb 05, 2024: Ventripoint Begins 2024 with Leadership Change
- 7.1.2 Jan 21, 2024: Dr. Luc Mertens, Head of Echocardiography at The Hospital for Sick Children, Joins Ventripoint's Clinical Advisory Board
- 7.1.3 Oct 23, 2023: Ventripoint to Hold Annual General Meeting of Shareholders on November 1, 2023
- 7.1.4 Oct 03, 2023: Ventripoint Announces Appointment of Chief Finance Officer
- 7.2 Financial Announcements
- 7.2.1 Mar 28, 2024: Ventripoint Diagnostics Provides Corporate Update and Announces Conference Call
- 7.2.2 Mar 22, 2024: Concha Receives FDA 510(k) Clearance for Sol Hearing Aid (CL-1001)
- 7.2.3 Nov 24, 2023: Ventripoint Announces Date and Timing for Release of Q3 2023 Financial Results and Webinar
- 7.2.4 Oct 26, 2023: Boston Scientific Announces Results for Third Quarter 2023
- 7.2.5 Aug 25, 2023: Ventripoint Announces Date and Timing for Release of Q2 2023 Financial Results and Webinar
- 7.2.6 Aug 09, 2023: Fluidai’s Artificial Intelligence-Powered Postsurgical Monitor, Stream Platform, Launches Globally
- 8 Appendix
- 8.1 Research Methodology
- 8.1.1 Coverage
- 8.1.2 Secondary Research
- 8.1.3 Primary Research
- 8.1.4 Market Modeling and Forecasting
- 8.1.5 Company Share Analysis
- 8.1.6 Distribution Share Analysis
- 8.1.7 Benchmarking
- 8.2 GlobalData Consulting
- 8.3 Contact Us
- 8.4 Disclaimer
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.